![logo](/logos/TYRA.webp)
Tyra Biosciences, Inc.
NASDAQ:TYRA
20.59 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Tyra Biosciences, Inc. |
Symbool | TYRA |
Munteenheid | USD |
Prijs | 20.59 |
Beurswaarde | 1,085,843,670 |
Dividendpercentage | 0% |
52-weken bereik | 10.38 - 24.25 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Todd Harris Ph.D. |
Website | https://www.tyra.bio |
An error occurred while fetching data.
Over Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)